HARMONY Trial : To Evaluate a Therapeutic and Monitoring Device(NOVAtria System) for Heart Failure Management
The Study of a tHerApeutic and monitoRing Device iMplanted at the Atrial Septum prOvides Heart Failure maNagement in sYmptomatic Patients (HARMONY Trial)
United Innomed(Shanghai) Limited
330 participants
Mar 1, 2026
INTERVENTIONAL
Conditions
Summary
The objective of the HARMONY trial is to evaluate the safety and efficacy of implantable left atrial pressure sensor and interatrial shunt system for the treatment of chronic heart failure with reduced left ventricular ejection fraction (HFrEF, EF ≤ 40%) and New York Heart Association(NYHA) functional Class II or Class III who at baseline are treated with guideline-directed drug and device therapies.
Eligibility
Inclusion Criteria8
- Age ≥ 18 years old
- Clinically diagnosed with chronic heart failure
- Receiving guideline directed medical and device therapy (GDMT) for heart failure
- Left ventricular ejection fraction (LVEF) ≤ 40% assessed by echocardiography
- New York Heart Association (NYHA) functional class II or III, with NYHA II criteria met simultaneously; for NYHA III, at least one of the following must be satisfied:
- At least one hospitalization for heart failure within the past 12 months;
- Elevated BNP or NT-proBNP within 3 months prior to enrollment (under normal sinus rhythm, NT-proBNP \> 900 pg/mL; under atrial fibrillation, NT-proBNP \> 1500 pg/mL; under normal sinus rhythm, BNP \> 300 pg/mL; under atrial fibrillation, BNP \> 500 pg/mL; BNP not applicable if the patient is using ARNI);
- Able to perform 6-minute walk test (6MWT), with a distance between 100 meters and 450 meters
Exclusion Criteria11
- Currently in an acute decompensation of chronic heart failure (hospitalization within 2 weeks prior to enrollment), refractory end-stage heart failure, or on the waiting list for heart transplantation (including LVAD indication);
- BMI \> 40 kg/m² or \< 18.5 kg/m²;
- Systolic blood pressure \<90 or ≥160 mmHg
- Moderate or severe aortic or mitral stenosis, or planned during the trial intervention for severe regurgitation of the aortic, mitral, tricuspid, or pulmonary valves;
- Coronary artery disease requiring revascularization;
- Hypertrophic cardiomyopathy, active myocarditis, cardiac tamponade or large pericardial effusion, congenital heart disease, or other causes of heart failure
- History of stroke, transient ischemic attack (TIA), deep vein thrombosis (DVT), or pulmonary emboli within the past 3 months
- Severe chronic lung disease requiring oxygen therapy or long-term corticosteroids;
- Surgery involving atrial septal puncture within 3 months before enrollment (e.g., mitral repair, atrial fibrillation ablation, LAA closure);
- Significant RV dysfunction - TAPSE \<12mm or RVFAC ≤25%
- eGFR \<25 ml/min/1.73 m\^2
Interventions
The NOVAtria System, therapeutic and monitoring device will be implanted at interatrial septum with minimally invasive cardiac catheterization procedure
Right heart catheterization and TEE
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07402239